Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Immunology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Lymphoma Clinical Trials

A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found (342) clinical trials

Safety and Efficacy Evaluation of IM19 Cells

Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies(including B-cell Acute lymphoblastic LeukemiaB-cell Chronic Lymphocytic LeukemiaNon-Hodgkin's lymphoma) and Determine the Best Dosage.

Phase

Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib Dasatinib and Prednisone

This is a Phase I, single-center, open label, prospective, single-arm, dose-escalation and multi-dose study evaluating the use of ibrutinib in combination with dasatinib and prednisone therapy.

Phase

Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma

The major aim of this research is to assess the feasibility, safety and effectiveness of CD19 CAR-T Cell Therapy for Relapsed/ Refractory Acute Lymphoblastic Leukemia/ B cell Lymphoma patients who have applied it.

Phase

A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma

The purpose of this study is the area under the curve (AUC) for GB241 and rituximab concentrations.

Phase

Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia

This is a single arm, open-label, multi-center, phase I study to determine the efficacy of CTL019 in patients with r/r B-cell ALL. The study will have the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Primary Follow-up, Secondary Follow-up (if applicable) and Survival Follow-up.

Phase

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

Randomised, double-blind, parallel group study to compare PK and PD profiles between IBI301 and rituximab in patients with CD20+ B-cell Lymphoma

Phase

CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

CAR-T cells have been validated effective in treating CD19 positive B cell lymphoma. Other lymphomas like Hodgkin's lymphoma and anaplastic large cell lymphoma are CD30 positive. In this study, a newly CD30 targeted CART therapy ICAR30 is designed to specifically kill those CD30 expressing malignancies including Hodgkin's lymphoma and CD30+ …

Phase

Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma

This is an open, single-arm,multicenter 2 phase clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of CD19 positive lymphoma. The study will be conducted using a phaseⅠ/Ⅱdesign the study will have the following sequential phases: part A (screening, leukapheresis, cell …

Phase

Pilot Study for Patients With Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma

This is an open label, single center, pilot study to evaluate the safety and tolerability, and differential persistence and engraftment of autologous T cells engineered to express a chimeric antigen receptor targeting CD19 which is linked either to the CD3 or CD3:4-1BB signaling chains in a competitive repopulation setting in …

Phase

Siplizumab Combination Chemotherapy and Rituximab in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin Lymphoma

OBJECTIVES: Primary - Determine the toxicity of siplizumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride, and rituximab (DA-EPOCH-R) in patients with chemotherapy-naive, CD2-expressing T-cell or natural killer (NK)-cell non-Hodgkin lymphoma. - Determine the maximum tolerated dose of siplizumab in combination with DA-EPOCH-R in these patients. Secondary …

Phase